Curis Inc is a biotechnology company that focuses on the development of innovative therapeutics for the treatment of cancer. The company specializes in targeted therapies that aim to address the underlying mechanisms of cancer growth and progression, leveraging its expertise in small molecules and antibody therapies. Curis's research and development efforts are geared toward advancing novel treatment options for patients with various types of malignancies, with the goal of improving outcomes and enhancing quality of life. Through partnerships and collaborations, Curis seeks to bring its promising discoveries from the laboratory to the clinical setting, ultimately striving to address unmet medical needs in oncology. Read More
Curis, Inc. (NASDAQ: CRIS) has caught the attention of the investment community today with its bullish price action. The company’s shares have moved 26.77% on the day to $16.99.
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.
U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session. Corcept Therapeutics Incorporated (NASDAQ: CORT) shares fell 21% to $26.07.
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints.
